<DOC>
	<DOCNO>NCT01513291</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy MK-6096 versus placebo prevent migraine participant episodic migraine . After 28-day Screening period baseline number monthly migraine day assess , participant randomize receive MK-6096 placebo 12-week Treatment Period . Participants complete 12 week Treatment Period receive drug placebo additional 2 week Run-out Period . Treatment assignment Run-out Period determine initial randomization . In Run-out Period , participant receive placebo Treatment Period continue receive placebo participant receive MK-6096 Treatment Period 2 receive either MK-6096 placebo 1:1 ratio . The hypothesis test study MK-6096 10 mg superior placebo reduce migraine frequency measure mean change baseline monthly migraine day average 12- week treatment period .</brief_summary>
	<brief_title>A Study Safety Efficacy MK-6096 Migraine Prophylaxis Participants With Episodic Migraine ( MK-6096-020 )</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History migraine without aura &gt; 1 year ≥4 ≤14 migraine day per month 3 month prior study Male , female reproductive potential , female reproductive potential pregnant pregnancy test agree use acceptable contraception Pregnancy , breastfeeding , expect become pregnant Planning donate egg sperm study within 90 day last dose study medication Basilar hemiplegic migraine headache &gt; 50 year old age migraine onset ≥15 headachedays per month medication take acute migraine headache 10 day per month three month prior study Migraine prophylactic medication ( defined medication take daily prevent migraine ) take 30 day prior study History narcolepsy , cataplexy , circadian rhythm disorder , parasomnia , sleep related breathe disorder , restless legs syndrome , periodic limb movement disorder , excessive daytime sleepiness difficulty sleep due medical condition ( e.g. , asthma , gastroesophageal reflux disease , etc . ) Clinical , laboratory , electrocardiogram ( ECG ) evidence uncontrolled hypertension , uncontrolled diabetes , human immunodeficiency virus ( HIV ) disease , significant pulmonary , renal , hepatic , endocrine , systemic disease Myocardial infarction , unstable angina , coronary artery bypass surgery , revascularization procedure , stroke , transient ischemic attack within 3 month study Other confound pain syndrome ( i.e. , condition require daily use opioids ) , psychiatric condition uncontrolled major depression , dementia significant neurological disorder migraine Imminent risk selfharm , base clinical interview response Columbia Suicidality Severity Rating Scale ( CSSRS ) , harm others . Exclude prospective participant reporting suicidal ideation intent , without plan past 2 month suicidal behavior past 6 month History malignancy ≤5 year prior study , except adequately treat basal cell squamous cell skin cancer situ cervical cancer History hypersensitivity two chemical class drug , include prescription overthecounter medication Recent history ( within past 1 year ) current evidence drug alcohol abuse `` recreational use '' illicit drug prescription medication Donated blood product phlebotomy &gt; 300 ml within 8 week study , intend donate blood product receive blood product within 30 day study throughout study Consumption 3 alcoholic drink per day Body Mass Index &gt; 40 kg/m^2 History transmeridian travel ( across &gt; 3 time zone ) shift work ( defined permanent night shift rotate day/night shift work ) within past 2 week anticipate need travel ( across &gt; 3 time zone ) time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>